英文原著

1. Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Independent and distinct associations of FABP4 and FABP5 with metabolic parameters in type 2 diabetes mellitus. Front Endocrinol (Lausanne) in press pubmed

2. Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy. Cardiovasc Diabetol 2020;19:89. pubmed

3. Hirai H, Higa M, Morimoto T, Sakuma M, Arasaki O, Nomiyama T, Node K, Ueda S. Shimabukuro M. Dissimilar effects of anagliptin and sitagliptin on lipoprotein subclass in standard or strong statin-treated patients with type 2 diabetes mellitus: a sub-analysis of the REASON Trial. J Clin Med 2020;9:93 pubmed

4. Machii N, Kudo A, Saito H, Tanabe H, Iwasaki M, Hirai H, Masuzaki H, Shimabukuro M. Walking speed is the sole determinant criteria of sarcopenia of mild cognitive impairment in Japanese elderly patients with type 2 diabetes mellitus. J Clin Med 2020;9:2133pubmed

5. Ma E, Ohira T, Sakai A, Yasumura S, Takahashi A, Kazama J, Shimabukuro M, Nakano H, Okazaki K, Maeda M, Yabe H, Suzuki Y, Kamiya K. Dietary patterns associated with cardiometabolic risks in Japan: the Fukushima Health Management Survey, 2011–2015. Nutrients2020;12:129pubmed

6. Maimaituxun G, Fukuda D, Izaki H, Hirata H, Kanayama H, Masuzaki H, Sata M, Shimabukuro M. Levels of adiponectin expression in peri-renal and subcutaneous adipose tissue and its determinants in human biopsied samples. Front Endocrinol (Lausanne) in press pubmed

7. Maimaituxun G, Yamada H, Fukuda D, Yagi S, Kusunose K, Hirata Y, Nishio S, Soeki T, Masuzaki H, Sata M, Shimabukuro M. Association of local epicardial adipose tissue depots and left ventricular diastolic performance in patients with preserved left ventricular ejection fraction. Circ J 2020;84:203-216 pubmed

8. Rahadian A, Fukuda D, Salim HM, Yagi S, Kusunose K, Yamada H, Soeki T, Shimabukuro M, Sata M. Thrombin inhibition by dabigatran attenuates endothelial dysfunction in diabetic mice. Vasc Pharmacol 2020;124:106632 pubmed

9. Saito H, Tanabe H, Kudo A, Machii N, Higa M, Yamaguchi S, Maimaituxun M, Abe K, Takahashi A, Tanaka T, Asahi K, Masuzaki H, Ohira H, Kazama JJ, Shimabukuro M. High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes. Sci Rep in press pubmed

10. Sakai A, Nakano H, Ohira T, Maeda M, Okazaki K, Takahashi A, Kawasaki Y, Satoh H, Ohtsuru A, Shimabukuro M, Hashimoto S, Hosoya M, Yasumura S, Ohto H, Kamiya K, the Fukushima Health Management Survey Group. Relationship between the prevalence of polycythemia and factors observed in the Mental Health and Lifestyle Survey after the Great East Japan Earthquake. Medicine (Baltimore) 2020;124:106632 pubmed

11. Tanabe H, Saito H, Kudo A, Machii N, Hirai H, Maimaituxun G, Tanaka K, Masuzaki H, Watanabe T, Asahi K, Kazama JJ, Shimabukuro M. Factors associated with risk of diabetic complications in novel cluster-based diabetes subgroups: a japanese retrospective cohort study. J Clin Med 2020;9:2083 pubmed

12. Tanabe H, Saito H, Machii N, Kudo A, Tanaka K, Asahi K, Kazama JJ. Shimabukuro M. Burden of undiagnosed type 2 diabetes in diabetic kidney disease: a japanese retrospective cohort study. J Clin Med 2020;9:2028 pubmed

13. Tanaka, A, Shimabukuro M, Machii N, Teragawa H, Okada Y, Shima K,  Takamura T, Taguchi I, Hisauchi I, Toyoda S, Matsuzawa Y, Tomiyama H, Yamaoka-Tojo M, Ueda S, Higashi Y, Node K. Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: the placebo-controlled double-blind randomized EMBLEM trial. J Diabetes Investig in press pubmed

14. Tanaka A, Shimabukuro M, Okada Y, Sugimoto K, Kurozumi A, Torimoto K, Hirai H, Node K. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial. Cardiovasc Diabetol 2020;19:85 pubmed

15. Yamaguchi S, Abe M, Iseki K, Arakaki T, Arasaki O, Shimabukuro M, Ueda S. Prognostic impact of the early changes in serum chloride level among hospitalized acute heart failure patients: A Retrospective Cohort Study. Circ Rep in press

16. Yamaguchi S, Manabe O, Abe M, Chiba I, Arasaki O, Shimabukuro M. Fractional flow reserve value of reverse redistribution in 201-thallium stress scintigraphy. Vasc Failure in press pubmed

17. Yamaguchi S, Oba K, Higa H, Arasaki O, Shimabukuro M. Age-dependent efficacy of ezetimibe for low-density lipoprotein cholesterol reduction in Japanese patients with or without type 2 diabetes mellitus. J Clin Med 2020;9:1675 pubmed

英文総説


和文著書

・島袋充生:SGLT2阻害薬を処方する際の禁忌や注意点. ひと味違うSGLT2阻害薬の考え方、使い方 中外医学社; 2020

・島袋充生 Metabolic syndrome and dyslipidemia メタボリックシンドロームと糖尿病(翻訳) The ESC Handbook on Cardiovascular Pharmacotherapy (2 Ed) Edited by Juan Carlos Kaski and Keld Per Kjeldsen 欧州心臓病学会(ESC)心血管薬物療法ハンドブック 日本語翻訳版 Oxford Univ Press, 2020, UK

和文総説

・島袋 充生 心臓脂肪・血管周囲脂肪と心臓血管病 糖尿病プラクティス 2020:37;421-425.

・平井裕之、島袋充生「糖尿病患者の心血管病罹患リスクにどう立ち向かうか」糖尿病患者の血糖,血圧,脂質管理はどうする? Heart and View 2020;125:227-230.

・山崎 聡, 尾形 絵美, 岡本 士毅, 島袋 充生, 益崎 裕章【高血圧診療Update-「高血圧治療ガイドライン2019」で何が変わるのか?】他疾患を合併する高血圧 肥満症・メタボリックシンドローム 内科 2020;125:227-230.

・山崎 聡, 尾形 絵美, 岡本 士毅, 島袋 充生, 益崎 裕章【新しい時代の高血圧診療】合併症を伴う高血圧の治療 脂質異常症・肥満症・高尿酸血症 他疾患を合併する高血圧 肥満症・メタボリックシンドローム 臨牀と研究2020:97;72-77.

・山崎 聡, 島袋 充生, 益崎 裕章 糖・脂質代謝領域における高血圧学の現状と展望 日本臨床 増刊号 高血圧学 2020 印刷中

和文症例

・伊藤 裕平, 神宮字 伸哉, 佐藤 祐介, 佐藤 拓, 村上 友太, 藤井 正純, 佐久間 潤, 岩崎 麻里子, 工藤 明宏, 島袋 充生, 喜古 雄一郎, 岡田 正康, 齋藤 清 腫瘍の局在診断に苦慮した症候性ACTHおよびGH産生性重複下垂体腺腫の1例 Neurological Surgery 2020:48:253-260

国際学会


国内学会